Clinical Trials Logo

Hepatitis C clinical trials

View clinical trials related to Hepatitis C.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04614142 Withdrawn - Clinical trials for End Stage Renal Disease

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

Start date: November 13, 2020
Phase: Phase 4
Study type: Interventional

This is a single patient, single center study evaluating if administration of pan-genotypic DAA therapy on day 3 (+/- 2 days) post-kidney transplant prevents the transmission of hepatitis C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.

NCT ID: NCT04546802 Withdrawn - Clinical trials for Hepatocellular Carcinoma

HepATocellular Cancer Hcv Therapy Study

HATCHeT
Start date: September 2019
Phase: Phase 3
Study type: Interventional

Subjects with Hepatitis C Virus (HCV) infection, genotype 1 or 4 and with hepatocellular carcinoma (HCC) and a complete response to HCC therapy will be randomised to immediate or delayed (6 months) HCV therapy with Elbasvir (MK-8742) and Grazoprevir (MK-5172) [EBR/GZR].

NCT ID: NCT04395118 Withdrawn - Clinical trials for Hepatocellular Carcinoma

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs

STOP-HCC
Start date: August 15, 2020
Phase: N/A
Study type: Interventional

The investigators will conduct a randomized controlled trial comparing two strategies to promote HCV screening, follow-up testing, and treatment among Parkland patients who are 18 years or older who have elevated liver functioning test (LFT) results: in reach with electronic medical record alerts and provider education vs. combination of in reach and provider education plus mailed outreach and patient navigation.

NCT ID: NCT04320290 Withdrawn - Hepatitis C Clinical Trials

HCV + to HCV - Kidney Transplant

Start date: May 21, 2020
Phase: Phase 4
Study type: Interventional

This is a single center study characterizing the experience of administration of 8 weeks of pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.

NCT ID: NCT04309734 Withdrawn - Hepatitis C Clinical Trials

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Start date: October 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study has two parts. Part A will assess the safety, tolerability and pharmacokinetics (PK) of AT-777 in healthy subjects. Part B will assess the safety, antiviral activity/efficacy and PK of AT-777 in combination with AT-527 after 8 weeks of treatment in HCV-infected subjects.

NCT ID: NCT04235049 Withdrawn - HCV Infection Clinical Trials

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

ECLIPSE
Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

Hepatitis C (HCV) is a chronic infection with significant morbidity and mortality. The development of directly acting antivirals (DAA) has dramatically improved the cure rate of HCV treatment. People who experience incarceration are disproportionately infected and often involved in ongoing transmission of disease. However, despite availability of effective treatment, people who experience incarceration are often unable to access this curative therapy, and are often not readily engaged in medical care upon release. This perpetuates transmission and progression of disease in an incredibly high risk, marginalized population. Therefore, in order to effectively eliminate HCV, it is imperative that the epidemic of HCV in prisons is addressed, and that models of care are established for treatment of HCV in incarcerated individuals, both during and after incarceration. As such, the investigators propose a comprehensive model of care to engage incarcerated individuals in treatment of HCV upon release from prison. This care is provided in conjunction with collocated services to prevent HCV reinfection, including opioid agonist therapy. This pilot trial will demonstrate whether a comprehensive model of care can effectively cure HCV in recently incarcerated individuals, while simultaneously treating opioid use disorder and preventing HCV reinfection.

NCT ID: NCT03794258 Withdrawn - HCV Infection Clinical Trials

Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2a, open-label, randomized study. The study is designed to test the hypothesis that the nucleoside inhibitor sofosbuvir combined with NS5A inhibitor daclatasvir and NS5B non-nucleoside inhibitor CDI-31244 with/without the protease inhibitor asunaprevir will result in high SVR rate with a shortened treatment duration (2 weeks) in non-cirrhotic HCV genotype 1b-infected subjects.

NCT ID: NCT03791814 Withdrawn - Hepatitis C Clinical Trials

A Prospective Cohort Study to Improve HCV Care in Dialysis Patients

MATCH-D
Start date: January 1, 2019
Phase: Phase 4
Study type: Interventional

Hepatitis C virus (HCV) infects an estimated 185 million individuals worldwide and 3.4 million to 4.4 million people in the United States. Approximately 80% of acutely infected HCV patients progress to chronic infection, 20% of whom develop cirrhosis within 25 years, with 25% of patients with cirrhosis developing hepatocellular carcinoma and/or decompensated liver disease. Hepatitis C virus is the primary cause of liver transplantation in the United States. There are 6 known genotypes of HCV. The most common genotypes in the United States are genotype 1 (subtypes 1a and 1b), 2, and 3, which together comprise 97% of all infections. In chronic kidney disease (CKD) patients, the prevalence of HCV infection is higher than in the general population. Patients with impaired kidney function have limited therapeutic options. The US Food and Drug Administration (FDA) recently approved Elbasvir/Grazopevir for treatment of genotype 1 and 4 infection in CKD patients including those on hemodialysis. At our institution, the Multidisciplinary Approach to the Treatment of Chronic Hepatitis C (MATCH) Initiative is a program which was first implemented to increase screening, diagnosis and treatment of HCV by actively incorporating primary care providers (PCP) at every step of the HCV care process. Following implementation of MATCH, early data indicates, marked increase in screening high risk and baby-boomer cohorts, as well as safe and effective treatment of HCV cases at the primary provider setting. The initiative proved that active participation of PCPs in the care of HCV reduced the treatment lag by 71% compared to traditional care of referring HCV cases to specialized care (Gastroenterology or Hepatology) while keeping similar SVR. We intend to expand the program to improve quality of care for HCV patients in dialysis center. We propose active involvement of dialysis clinical staff including nephrologist, to increase HCV screening rate, promote timely diagnosis and treatment of CHC in patient with end-stage renal disease. This study is being conducted to evaluate real-world effectiveness of HCV DAA therapy in CHC hemodialysis patients when the DAA-treatment is managed and monitored by the clinical staff of hemodialysis center. Primary objective: To determine sustained virologic response (SVR) rates attained with open-label Zepatier administered through hemodialysis center under the supervision of a nephrologist in chronic hepatitis C infected (CHC) patient currently on hemodialysis. Secondary objective: 1. To estimate prevalence of HCV infection, severity of fibrosis (using non-invasive measures), and HCV detection rate in patients with End stage renal disease on hemodialysis. 2. To calculate the average treatment-lag time (time from HCV diagnosis to submission of treatment approval).

NCT ID: NCT03702218 Withdrawn - Hepatitis C Clinical Trials

Hepatitis C Positive Donor Into Hepatitis C Negative Recipients

Start date: July 1, 2019
Phase: Early Phase 1
Study type: Interventional

Despite many efforts to increase the size of the donor pool, there is a large and growing disparity between the number of donor kidneys and livers available for transplantation and the number of patients on the transplant waiting list. New donor pools are needed to satisfy the lack of available donor organs, along with expanded criteria for the existing donor pools. A new standard of care now exists at most local and regional transplant centers. This new standard of care is based on the use of multiple direct-acting antiviral agents (DAAs) for treatment of hepatitis C virus (HCV) that have been approved by the Food and Drug Administration (FDA) for the treatment of hepatitis C and are associated with high HCV cure rates and minimal side effect profiles. The efficacy and tolerability of these medications has allowed the expansion of the available donor pool by making HCV antibody positive non viremic organs and HCV-viremic organs (when HCV is detectable in the blood) available to HCV-naive recipients on the organ transplantation waiting list. Expansion of this donor pool may decrease time on the waiting list and improve quality of life and survival while waiting for organ transplantation. Study Aim: We propose a clinical protocol to utilize solid organs from exposed and/or HCV-viremic organ donors for transplantation into HCV negative recipients. The primary purpose of the clinical protocol is to: Collect prospective standard of care laboratory data on the results of these interventions

NCT ID: NCT03639207 Withdrawn - Hepatitis C Virus Clinical Trials

IFNL4 Genotype for Predicting Response to Ledipasvir/Sofosbuvir

Start date: June 15, 2018
Phase:
Study type: Observational

Background: Hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma and end-stage liver disease. Ledipasvir/sofosbuvir is used to treat chronic HCV. The drug name for it is Harvoni. It is a very effective treatment, but it is expensive. Researchers have found a genetic variation that predicts how people will respond to this treatment. They want to learn more about this genetic link. It could help develop better treatments for HCV. Objective: To study if certain inherited genetic differences and other factors affect the different ways patients respond to treatment with Harvoni. Eligibility: Adults ages 18 who are members of the Kaiser Health Plan and have recently been treated for hepatitis C with Harvoni Design: Researchers will review medical records to identify a group of people who could be in the study. Participants will provide a saliva sample at home. They will get instructions and kit to collect it in. Participants will spit into a funnel until it reaches a mark on the funnel. It will be about 1 teaspoon of saliva with no bubbles. They will return the sample in a prepaid mailer. Researchers will do genetic tests on the samples. The participant data will be kept confidential. It will not be given to insurance companies. Participants will not be given any test results. ...